Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology.

ABSTRACT: Hemophilia A (HA) and hemophilia B (HB) are rare disorders, being caused by the total lack or under-expression of two factors from the coagulation cascade coded by genes of the X chromosome. Thus, in hemophilic patients, the blood does not clot properly. This results in spontaneous bleeding episodes after an injury or surgical intervention. A patient-centered regimen is considered optimal. Age, pharmacokinetics, bleeding phenotype, joint status, adherence, physical activity, personal goals are all factors that should be considered when individualizing therapy. In the past 10 years, many innovations in the diagnostic and treatment options were presented as being either approved or in development, thus helping clinicians to improve the standard-of-care for patients with hemophilia. Recombina

SUBMITTER: Hotea I 

PROVIDER: S-EPMC8339806 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature